{"Clinical Trial ID": "NCT01419197", "Intervention": ["INTERVENTION 1:", "- Trastuzumab Emtansine", "- Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or impossible to manage toxicity.", "INTERVENTION 2:", "Treatment of doctor's choice", "Treatment of the physician's choice until disease progression (as assessed by the investigator) or impossible toxicity. Treatments included mono-agent chemotherapy, mono-agent or double-agent hormone therapy for hormone positive receptor disease, and HER2-directed treatment."], "Eligibility": ["Incorporation criteria:", "\u2022 Adult participants aged 18 years.", "A histologically or cytologically documented breast cancer.", "A metastatic or non-resectable locally advanced/recidive breast cancer.", "HER2-positive disease by prospective laboratory confirmation.", "The progression of the disease during the last treatment received as defined by the investigator.", "Prior treatment with trastuzumab, taxane and lapatinib.", "The progression of the disease after at least two treatment regimens directed by HER2 in a locally advanced/recurrent metastatic or non-resectable context.", "A suitable organ function, as demonstrated by the laboratory results.", "The Eastern Cooperative Oncology Group (ECOG) has a yield of 0, 1, or 2.", "The left ventricular ejection fraction (LVEF) 50% by echocardiogram or multi-door acquisition scan.", "- Exclusion criteria:", "- Chemotherapy 21 days prior to the first treatment study.", "- Trastuzumab 21 days before the first study.", "- Lapatinib 14 days before the first study.", "A pre-registration in a study containing trastuzumab emtansin, whether or not the patient has received trastuzumab emtansin.", "- Untreated or symptomatic brain metastases, or requiring radiotherapy, surgery or corticosteroids to control symptoms within one month of randomization."], "Results": ["Performance measures:", "- Survivors without progression", "The period of progression-free survival was defined as the period from randomization to the first documented progression of the disease by the investigator's assessment using the criteria for assessing response in solid tumours (RECIST) v1.1 or death of any cause, whichever occurs first.", "Timeline: Baseline to the clinical deadline of February 11, 2013 (up to 2 years)", "Results 1:", "Title of the arm/group: Trastuzumab Emtansine", "Description of the arm/group: Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or toxicity impossible to manage.", "Total number of participants analysed: 404", "Median (95% confidence interval)", "Unit of measure: Month 6.2 (5.59 to 6.87)", "Results 2:", "Title of the arm/group: Treatment of the doctor's choice", "The treatment included mono-agent chemotherapy, mono-agent or double-agent hormone therapy for hormone positive receptor disease, and HER2-directed treatment.", "Total number of participants analysed: 198", "Median (95% confidence interval)", "Unit of measure: Month 3.3 (2.89-4.14)"], "Adverse Events": ["Undesirable Events 1:", "Total: 102/403 (25.31%)", "Anemia 1/403 (0.25%)", "Febrile neutropenia 1/403 (0.25%)", "Granulocytopenia 0/403 (0.00 %)", "Neutropenia 1/403 (0.25%)", "Thrombocytopenia 1/403 (0.25%)", "Heart failure 1/403 (0.25%)", "Vertigo 1/403 (0.25%)", "Hypercalcaemia of malignancy 0/403 (0.00 %)", "1/403 blurred vision (0.25%)", "Abdominal disorders 0/403 (0.00 %)", "Abdominal pain 4/403 (0.99%)", "Adverse Events 2:", "Total: 41/184 (22.28 per cent)", "Anemia 2/184 (1.09%)", "7/184 (3.80%)", "Granulocytopenia 1/184 (0.54%)", "Neutropenia 2/184 (1.09%)", "Thrombocytopenia 1/184 (0.54%)", "- Heart failure 0/184 (0.00 %)", "Vertigo 0/184 (0.00 %)", "Hypercalcaemia of malignancy 1/184 (0.54%)", "The vision is blurred 0/184 (0.00 %)", "Abdominal disorders 1/184 (0.54%)", "Abdominal pain 3/184 (1.63%)"]}